Best Life Sciences Companies in Helsinki, Finland
The 65 best Life Sciences companies in Helsinki, Finland in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: Nanoform.
Our analysis of 576 Life Sciences companies
$91.7b in tracked funding; 70% of the stack-profiled cohort runs cloud-native; funding activity peaked in 2025.
Ranked: Best Life Sciences companies in Helsinki
| # | Company | Disclosed funding | Last round | Employees | Founder | Tech stack | Web popularity | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|---|
| 1 | Nanoform Provider of a platform for the development of nano particles | $48M | 28 mo ago | 158 | Jouko Yliruusi Co-Founder | WordPressApple iCloud MailMicrosoft 365+22 | Top 5M | — | — |
| 2 | Nexstim Provider of noninvasive brain stimulation for rehabilitating stroke patients | $30M | 101 mo ago | 37 | Mikko Karvinen Chief Executive Officer | TYPO3 CMSPHPSalesforce+12 | Top 10M | 135 patents Advanced navigated transcranial magnetic stimulation devices and therapeutic pulse protocols. | — |
| 3 | TILT Biotherapeutics Developer of oncolytic viral immunotherapies for solid tumors | $29M | 13 mo ago | 21 | Akseli Hemminki Chief Executive Officer | WordPressMySQLPHP+10 | Top 50M | 73 patents Oncolytic viral therapies and adoptive cell immunotherapies targeting cancer and microbiome. | — |
| 4 | Mendor Blood glucose monitoring device | $28M | 122 mo ago | 16 | — | — | — | 31 patents Blood glucose monitoring devices and calibrated test‑strip cartridge technologies | — |
| 5 | Valo Therapeutics Developer of immunotherapies for cancer and infectious disease | $25M | 15 mo ago | 20 | — | DrupalPHPNginx+11 | Top 50M | 61 patents Oncolytic viral vector platforms for cancer immunotherapy and vaccine development | — |
| 6 | Nightingale Provider of a metabolomic technology platform for blood analysis and research | $23M | 65 mo ago | 64 | — | VimeoApache HTTP ServerAmazon Web Services+14 | Top 5M | — | — |
| 7 | Aiforia Provider of an AI and cloud-based, deep learning image analysis platform in all therapy areas | $23M | 6 mo ago | 3 | Jukka Tapaninen CEO | HubSpot CMS HubApple iCloud MailGoogle Workspace+26 | Top 5M | — | — |
| 8 | Algorithmiq Developer of quantum algorithms for chemistry and life science applications | $20M | 1 mo ago | 24 | Sabrina Maniscalco Co-Founder & CEO | WordPressApple iCloud MailMicrosoft 365+16 | Top 10M | 26 patents Quantum algorithms for expectation estimation, noise mitigation, and fermionic encoding in quantum computing | 1 expansion |
| 9 | Aplagon Heparin peptidoglycan mimetics for treating complications of vascular intervention-related blood vessel… | $19M | 16 mo ago | 1 | Riitta Lassila Co-Founder | — | — | 32 patents Heparin‑protein conjugate antithrombotic drugs for thrombocytopenia treatment | — |
| 10 | CurifyLabs Provider of digital 3D printing solutions for personalized medicine | $11M | 12 mo ago | 16 | Niklas Topelius Co-Founder | HubSpot CMS HubFacebook LoginLinkedin Sign-in+20 | Top 50M | 12 patents Advanced pharmaceutical formulation and dispensing systems, including blade‑free mixing and printable doses. | — |
| 11 | Rappta Therapeutics Provider of a small molecule drug discovery platform for cancer | $11M | 68 mo ago | 11 | Sunjeet Sawhney Chief Executive Officer; Board Member | — | — | 28 patents Small-molecule aromatic PP2A modulators for therapeutic enzyme regulation | — |
| 12 | Woodcast Provider of wooden material for casting and occupational therapy | $11M | 134 mo ago | — | Jari Salo Founder | — | — | — | — |
| 13 | Linio Biotech Developer of medical device for skin and tissue regeneration | $10M | 31 mo ago | 11 | Timo Ylikomi Co-Founder & CMO | — | — | 13 patents Cell‑free adipose‑derived therapeutic preparations for regenerative and cosmetic medicine | — |
| 14 | Sooma Oy Non-invasive neuromodulation therapies | $7M | 27 mo ago | 22 | — | Cart FunctionalityShopifyShop Pay+28 | Top 5M | 32 patents Non-invasive and implantable transcranial brain stimulation devices and electrodes | — |
| 15 | Oncos Therapeutics Provider of precision orthopaedics and musculoskeletal oncology solutions | $6M | 193 mo ago | 11 | — | WordPressMySQLPHP+23 | Top 5M | 62 patents Patents concentrated in health & consumer products | — |
| 16 | Plexpress High throughput gene expression analysis | $4M | 170 mo ago | — | Juhani Lahdenpera CEO | — | — | — | — |
| 17 | PlexPress Tools for gene expression analysis | $4M | 170 mo ago | — | Juhani Lahdenpera Founder & CEO | — | — | — | — |
| 18 | Veri Provider of a continuous glucose monitor for measuring blood glucose levels | $4M | 60 mo ago | 48 | Verneri Jaamuru Co-Founder | PrismicSentryNode.js+29 | Top 5M | — | — |
| 19 | Askel Healthcare Developer of regenerative medicines for cartilage & bone tissue regeneration | $3M | 53 mo ago | 8 | Anne Haaparanta Co-Founder & CTO | — | — | 18 patents Patents concentrated in health & consumer products | — |
| 20 | TENBORON Developer of boron carrier antibodies for the treatment of cancer | $2M | 86 mo ago | 2 | Juha Jouhki Chief Executive Officer | — | — | 19 patents Boronated EGFR1‑targeted antibody conjugates for BNCT cancer therapy | — |
| 21 | GlucoModicum Developer of needle-free glucose monitoring technology for personal health solutions | $1M | 52 mo ago | 37 | Johan Bobacka Co-Founder | WordPressApple iCloud MailMicrosoft 365+16 | Top 50M | 34 patents Continuous glucose monitoring and interstitial fluid biosensor technologies | — |
| 22 | Uute Scientific Provider of natural extract products for treating immune-mediated diseases | $1M | 53 mo ago | 10 | Oliver Boldt Chief Sales Officer and Co-Founder | WordPress Block EditorwpBakeryWordPress+32 | Top 50M | — | — |
| 23 | Veil Provider of AI and ML based big data analytics and data anonymization solutions | $1M | 46 mo ago | 12 | Tuomo Pentikainen CEO | WordPressApple iCloud MailGoogle Workspace+27 | Top 50M | — | — |
| 24 | Solu Cloud based platform for real time genomic pathogen surveillance and epidemiology | $1M | 36 mo ago | — | Timo Moilanen Co-Founder | WebflowSentryWistia+12 | Top 50M | — | 1 launch |
| 25 | MediSapiens Clinical insights through Bioinformatics | $1M | 192 mo ago | 12 | — | — | — | 21 patents Computational analysis of biological samples and genomic health assessment | — |
| 26 | Neurotar In vivo imaging and image analysis company | $644K | 145 mo ago | — | Katja Karelina CEO | Cart FunctionalityWooCommerceWordPress+24 | Top 50M | 5 patents Patents concentrated in health & consumer products | — |
Top 12 Life Sciences companies in Helsinki
#1
Series B · Helsinki, Uusimaa · founded 2020 · 24 employees$20Mraised▾
Developer of quantum algorithms for chemistry and life science applications. The company develops algorithms that integrate classical and quantum computers. These algorithms address complex problems in quantum chemistry. They also offer solutions for drug discovery and development, targeting rare diseases. The company publishes research in peer-reviewed journals.
- May 2026Series B$21.2M
- Jun 2023Series A$15M
- Feb 2022Seed$5M
#2
Public · Helsinki, Uusimaa · founded 2014 · 3 employees$23Mraised▾
Provider of an AI and cloud-based, deep learning image analysis platform in all therapy areas. It provides analysis of digital pathology images for pathologists and researchers. The products are aiforia create, aiforia on-demand, and aiforia cloud.
- Dec 2025Post IPO$4.9M
- Jun 2021Series B$15.4M
- Feb 2021Grant (prize money)$483.6K
- Nov 2019Grant (prize money)$2.3M
#3
Series B · Helsinki, Uusimaa · founded 2013 · 21 employees$29.1Mraised▾
Developer of oncolytic viral immunotherapies for solid tumors. It has patented technology which uses oncolytic viruses to enhance tumor infiltrating lymphocyte therapy and chimeric antigen receptor (CAR) T-cell therapy. The lead product is a cytokine-armed oncolytic adenovirus for platinum-resistant ovarian cancer and also include other therapies for solid tumor.
- May 2025Series B$25M
- Feb 2023Grant (prize money)$2.3M
- Feb 2023Series B$6.3M
- Jul 2022Grant (prize money)$2.2M
#4
Series B · Helsinki, Uusimaa · founded 2016 · 20 employees$25.2Mraised▾
Developer of immunotherapies for cancer and infectious disease. The company uses immunogenic viruses as active carriers of tumor-specific peptides to direct the immune system to specifically target and kill cancer cells. The proprietary PeptiCRAd platform, an oncolytic adenovirus with immunogenic tumor peptides adsorbed onto the negatively charged viral capsid.
- Mar 2025Series B$20.6M
- Apr 2023Grant (prize money)$326.1K
- Nov 2021Series A$12.8M
- Feb 2020Seed$1.2M
#5
Series A · Helsinki, Uusimaa · founded 2021 · 16 employees$11.5Mraised▾
Provider of digital 3D printing solutions for personalized medicine. The company has developed a platform that enables sustainable, quality-controlled production of personalized medicine through its pharmaceutical printing technology. It is a smart drug formulation platform that incorporates cutting-edge technology to redefine the drug compounding process.
- May 2025Conventional Debt$1.1M
- May 2025Series A$7.6M
- Apr 2023Grant (prize money)$2.7M
- Jan 2023Grant (prize money)—
#6
Series A · Helsinki, Uusimaa · founded 2009 · 1 employees$19.5Mraised▾
Aplagon is a Finnish, preclinical stage biotech developing Heparin peptidoglycan mimetics for treating complications of vascular intervention-related blood vessel occlusions. The Heparin peptidoglycan mimetics, are called APACs and are proprietary, locally acting, potent antithrombotic products, which target blood vessel wall injury. APACs, which were discovered by Aplagon scientists, are indicated for the prevention and management of both the short- and long -term complications of vascular intervention-related blood vessel occlusions.
- Feb 2025Series A$7.2M
- Sep 2022Grant (prize money)$2.1M
- 2022Grant (prize money)$10.1M
- Dec 2018Seed—
#7
Public · Helsinki, Uusimaa · founded 2008 · 158 employees$47.5Mraised▾
Provider of a platform for the development of nanoparticles. The company uses its multi-patented Controlled Expansion of Supercritical Solutions (CESS) for the development of API nanoparticles directly from the solution. The technology is based on the bottom-up method of recrystallization. It increases the dissolution and bioavailability of nanoparticles and also helps to cross the blood-brain barrier (BBB) for the treatment of CNS disorders such as Alzheimer’s and Parkinson’s disease.
- Feb 2024Grant (prize money)—
- Mar 2021Post IPO$47.5M
#8
Series B · Helsinki, Uusimaa · founded 2013 · 22 employees$6.6Mraised▾
Sooma Oy is developing a non-invasive brain stimulation device, a treatment option for major neurological and psychiatric disorders. Initial product tDCS targets major depressive disorder and is CE Marked.
- Mar 2024Series B$5.5M
- Jun 2022Grant (prize money)$52.4K
- Jul 2020Grant (prize money)$1.8M
- Dec 2019Grant (prize money)$278.7K
#9
Series A · Helsinki, Uusimaa · founded 2017 · 11 employees$9.8Mraised▾
Developer of medical device for skin and tissue regeneration. The company offers a cell-free tissue product for skin restoration and soft tissue repair such as scar repair, skin rejuvenation, and wound treatment.
- Nov 2023Series A$4.6M
- 2023Grant (prize money)—
#10
Public · Helsinki, Uusimaa · founded 2000 · 37 employees$29.7Mraised▾
Provider of noninvasive brain stimulation for rehabilitating stroke patients. The company is developing Navigated Brain Stimulation (NBS) - noninvasive, image-guided transcranial magnetic stimulation (TMS) for brain diagnostics and therapy.
- Jan 2018Conventional Debt$1.2M
- Dec 2017Venture Debt$4.7M
- Oct 2017Post IPO$2.1M
- Dec 2014Post IPO$3.7M
#11
Public · Helsinki, Uusimaa · founded 2013 · 64 employees$23Mraised▾
Provider of a metabolomic technology platform for blood analysis and research. The company has proprietary mass-scale blood analysis technology the company has developed disease detection tests. The platform utilizes NMR spectroscopy to directly measure 220 metabolites in the blood sample to look for signatures indicative of diseases such as diabetes and cardiovascular disease. The company's platform can also be used for biomarker discovery to develop new tests.
- Jan 2021Grant (prize money)$308.4K
- Dec 2019Seed—
- Jan 2019Conventional Debt$22.7M
#12
Acqui-Hired · Helsinki, Uusimaa · founded 2006 · 16 employees$28.1Mraised▾
Mendor is a startup which has designed, developed and commercializes glucose monitoring system. Offers the Discreet blood-glucose meter and Balance online software. Discreet is described as an all-in-one blood-glucose monitoring system, while Balance is a cloud-based data-analysis platform that allows users to store and share individual data on glucose-levels. Integrates all - blood glucose meter, test strips and a lancing pen into one device.
- Mar 2016Series C$1.2M
- Jul 2014Series C$8.8M
- Jan 2014Series C$6.4M
- Jun 2011Series B$11.7M
Funding & investor landscape
Notable founders
Market landscape — 10 sub-themes by coverage
Share of Life Sciences coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
What Helsinki researches in biotechnology
- University of Helsinki28
- Helsinki University Hospital11
- Helsinki Institute of Physics11
- Helsinki Children\'s Hospital2
- Helsinki Art Museum1
Common questions
Rohit lives in the feed. He covers what's moving right now — the funding rounds, launches and shifts breaking across the trade press — and ties them back to where the sector is heading.